NCT01651949View on ClinicalTrials.gov

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

PHASE3CompletedINTERVENTIONAL
Enrollment

2,520

Participants

Timeline

Start Date

October 29, 2012

Primary Completion Date

August 4, 2014

Study Completion Date

August 4, 2014

Conditions
Genital WartsAnal CancerAnal Intraepithelial Neoplasia
Interventions
BIOLOGICAL

9vHPV Vaccine

9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01651949 - Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) | Biotech Hunter | Biotech Hunter